Shots:

• Inotiv to acquire Plato BioPharma for $15.0M that consist of $10.0M in cash- $2.0M in Inotiv's common shares (57-587) based on the average closing price for 20 trading-day period ends on Sept 29- 2021- $3.0M in unsecured promissory notes
• The acquisition will bolster PBI’s growing discovery operations in the Boulder- Colorado & expands its business to supports the growing demand for services
• After closing the transaction- Inotiv expects to retain all of PBI's 34 employees. Plato focusses on cardiovascular- renal- pulmonary- and hepatic therapeutic areas

| Ref: Globe Newswire | Image: Inotiv